

This article was downloaded by: [31.11.10.225]

On: 04 November 2014, At: 12:31

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Temperature

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ktmp20>

Effects of MDMA on body temperature in humans

Matthias E Liechti^a

^a Division of Clinical Pharmacology and Toxicology; Department of Biomedicine and Department of Clinical Research; University Hospital and University of Basel; Switzerland
Published online: 31 Oct 2014.



CrossMark

[Click for updates](#)

To cite this article: Matthias E Liechti (2014): Effects of MDMA on body temperature in humans, *Temperature*, DOI: [10.4161/23328940.2014.955433](https://doi.org/10.4161/23328940.2014.955433)

To link to this article: <http://dx.doi.org/10.4161/23328940.2014.955433>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.

Effects of MDMA on body temperature in humans

Matthias E Liechti*

Division of Clinical Pharmacology and Toxicology; Department of Biomedicine and Department of Clinical Research; University Hospital and University of Basel; Switzerland

Keywords: hyperthermia, hyperpyrexia, MDMA, norepinephrine, serotonin, treatment

Abbreviations: MDMA, 3,4-methylenedioxymethamphetamine

Hyperthermia is a severe complication associated with the recreational use of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). In this review, the clinical laboratory studies that tested the effects of MDMA on body temperature are summarized. The mechanisms that underlie the hyperthermic effects of MDMA in humans and treatment of severe hyperthermia are presented. The data show that MDMA produces an acute and dose-dependent rise in core body temperature in healthy subjects. The increase in body temperature is in the range of 0.2–0.8°C and does not result in hyperpyrexia (>40°C) in a controlled laboratory setting. However, moderately hyperthermic body temperatures >38.0°C occur frequently at higher doses, even in the absence of physical activity and at room temperature. MDMA primarily releases serotonin and norepinephrine. Mechanistic clinical studies indicate that the MDMA-induced elevations in body temperature in humans partially depend on the MDMA-induced release of norepinephrine and involve enhanced metabolic heat generation and cutaneous vasoconstriction, resulting in impaired heat dissipation. The mediating role of serotonin is unclear. The management of sympathomimetic toxicity and associated hyperthermia mainly includes sedation with benzodiazepines and intravenous fluid replacement. Severe hyperthermia should primarily be treated with additional cooling and mechanical ventilation.

Introduction

Hyperpyrexia (body temperature >40°C) is the most important acute severe complication of the recreational use of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). MDMA-induced hyperpyrexia is relatively rare and not observed in placebo-controlled studies in humans. However, moderate effects of MDMA on body temperature have been documented in several placebo-controlled laboratory studies in human subjects. This review summarizes the clinical studies on MDMA-induced hyperthermic effects and the potential pharmacological mechanisms that are involved in humans. Many preclinical studies (for review, see¹) but relatively few clinical studies have evaluated the effects of MDMA on body temperature. The present review focuses on the findings from placebo-controlled studies that assessed MDMA in humans and addresses treatment options for hyperpyrexia caused by recreational Ecstasy use. The thermal effects of Ecstasy in dance clubbers have previously been described and summarized.²

Hyperthermia associated with Ecstasy use

The association between Ecstasy use and hyperpyrexia is well-established,^{3–6} and reports were systematically compiled by Grunau and colleagues.⁶ Hyperpyrexia is relatively rare, but if it occurs, then it typically leads to intravascular coagulation,

rhabdomyolysis, and renal or other organ failure.^{2,4–10} In particular, body temperature >41°C can result in fatalities.^{4,6} Moderate forms of Ecstasy-induced hyperthermia (>38°C) are frequently observed. Increased body temperature (>37.1°C) was found in 19% of patients,⁹ and hyperthermia (>38°C) was found in 4% of patients⁵ who presented in emergency departments with Ecstasy-related medical problems.

Basic mechanisms involved in hyperthermia

Drug-induced hyperthermia resembles heat stroke. The basic mechanisms include increased heat production and/or decreased heat loss (Fig. 1). In heat stroke, heat dissipation is primarily impaired by a hot environment, and heat generation is often increased by exertion. In drug-induced hyperthermia, the drug exerts direct actions to increase metabolic heat generation and reduce heat dissipation as mostly studied in animals,^{7,11–13} whereas a hot environment and exertion may act as additional permissive factors.^{2,14} Additionally, in the case of drug-induced hyperthermia, central heat regulation mechanisms may be disturbed.¹² Many psychotropic substances, including both therapeutic medications and recreational drugs, alter body and brain temperature¹⁵ and may cause hyperthermia.¹² Serotonin syndrome, which includes increases in body temperature, may result when serotonergic drugs are used at high doses or in combinations.¹⁶ Neuroleptic malignant

© Matthias E Liechti

*Correspondence to: Matthias E Liechti; Email: matthias.liechti@usb.ch

Submitted: 07/12/2014; Revised: 07/12/2014; Accepted: 07/28/2014

<http://dx.doi.org/10.4161/23328940.2014.955433>

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License <http://creativecommons.org/licenses/by-nc/3.0/>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.




Figure 1. Basic mechanism involved in 3,4-methylenedioxymethamphetamine (MDMA)-induced hyperthermia.

syndrome is an adverse hyperthermic reaction to antipsychotic drugs.¹² MDMA releases serotonin and therefore may induce a serotonin syndrome, including increased body temperature.¹⁷ Additionally, MDMA has been shown to induce alterations in mitochondrial energy metabolism in animals, resulting in increased heat generation instead of metabolic energy carrier (i.e., adenosine triphosphate) production.^{11,18} Additionally, psychostimulants, including MDMA, constrict blood vessels via sympathetic stimulation, including adrenergic receptor stimulation, thereby reducing peripheral blood flow and heat dissipation by convection via the skin (Fig. 1).¹⁹ Furthermore, central thermoregulation may be dysregulated in the case of substances that act as direct or indirect serotonin receptor agonists, such as MDMA.²⁰ Dopaminergic mechanisms have also been implicated in MDMA-induced hyperthermia in pre-clinical studies.²¹ Many permissive factors have been shown to enhance the thermogenic effects of MDMA, typically in preclinical studies, and have been summarized with regard to human MDMA use.² Factors that increase the risk of MDMA-induced hyperthermia in animals and possibly also in humans include multiple dosing (booster) or high doses,^{2,22} high ambient temperature,^{7,23,24} reduced fluid intake,²³ crowded conditions, physical activity,²³ and social interaction.^{24,25} Several of these risk factors are typically present in dance clubs or party settings where MDMA and other stimulant drugs are consumed. Hyperthermia is also seen in human MDMA exposure outside “rave” party settings in the absence of physical activity.²⁶ In placebo-controlled laboratory studies in humans, these conditions are mostly not present for safety reasons. In real-world studies of ecstasy users at dance clubs, increases in tympanic body temperature of +0.2 to +1.6°C have been measured in response to Ecstasy use (for a summary, see Parrott²).

Effects of MDMA on body temperature in experimental clinical studies

Clinical laboratory studies that investigated the effects of MDMA using a placebo-controlled study design are summarized

in Table 1. MDMA was administered orally in all these studies but different doses were used. A series of small experimental studies ($n < 20$) assessed the thermogenic effects of MDMA in healthy subjects.²⁷⁻⁴⁰ These studies typically used axillary, oral, or tympanic temperature measurements. Body temperature was not the primary outcome measure in these studies, with one exception. Pooled analyses of the effects of MDMA have been reported using aggregated data from smaller studies with 27 subjects by da la Torre and colleagues,⁴¹ 74 subjects by Liechti and colleagues,³⁴ and 80 subjects by Hysek and Liechti.³² In the studies by Liechti and colleagues,⁴²⁻⁴⁶ which were conducted in Zurich, Switzerland, axillary body temperature was measured in a total of 54 men and 20 women after MDMA doses of 1.35-1.8 mg/kg.³⁴ Peripheral body temperature was significantly increased by 0.4°C compared with placebo in male subjects, whereas MDMA-induced increases in body temperature did not reach statistical significance in the smaller group of female participants.³⁴ All axillary body temperatures remained below 38°C.³⁴ In our more recently published placebo-controlled studies performed in Basel, Switzerland, core body temperature was measured using an ear thermometer and repeatedly after the administration of MDMA at doses of 75 mg ($n = 30$) and 125 mg ($n = 96$) in a total of 126 healthy subjects.²⁷⁻³³ The effects of the 75 mg dose of MDMA on body temperature were reported by Schmid et al.⁴⁷ The effects of the 125 mg dose of MDMA were reported in a pooled analysis by Hysek and Liechti ($n = 80$)³² and separately for 16 additional subjects.^{33,47} MDMA did not significantly alter body temperature at a dose of 75 mg compared with placebo in 30 subjects.⁴⁷ The maximum increase after MDMA was $0.35 \pm 0.06^\circ\text{C}$ above pretreatment baseline compared with $0.25 \pm 0.06^\circ\text{C}$ after placebo.⁴⁷ At a higher dose of 125 mg, MDMA robustly and significantly increased body temperature in several of our recent studies.^{27,28,30,31,33} The pooled data from 5 of these studies were presented in an analysis of the autonomic effects of MDMA in 80 healthy subjects³² and in a study of dose-response effects in the online supplemental material that accompanied the reported by Schmid et al.⁴⁷ The increase in body temperature after 125 mg of MDMA was typically 0.3-0.8°C.^{32,47} As expected, a statistically significant MDMA dose-response effect on body temperature was observed.⁴⁷ Maximal temperatures occurred 2-2.5 h after MDMA administration and after subjective effects, heart rate, or blood pressure had peaked, which was at 1.5 h.³² An analysis of the data from all 126 subjects showed a peak maximum body temperature of $37.5 \pm 0.5^\circ\text{C}$. After the 75 mg dose of MDMA, tympanic temperatures remained below 38°C in all 30 subjects. However, after the 125 mg dose in a total of 96 subjects, tympanic temperatures were $>38.0^\circ\text{C}$ in 21 subjects (22%) and $>38.5^\circ\text{C}$ in 3 subjects (3%), reaching a maximum of 39.1°C in one subject (1%). Importantly, these body temperatures were measured with subjects at rest and at a mean room temperature of $22.7 \pm 0.6^\circ\text{C}$. The time course of the increase in tympanic body temperature after MDMA administration at a dose of 125 mg in 96 subjects is shown in Figure 2. The figure shows the pooled data from all our 6 published studies using the 125 mg dose of MDMA.^{27-31,33} Significant elevations in body

Table 1. Placebo-controlled studies that investigated effects of MDMA on body temperature

Reference	other drugs in study	Sample size	oral doses	measurement	effect
39	no	n = 6	0.25-1.0 mg/kg	oral	no significant change
42	no	n = 13	1.7 mg/kg	axillary	no significant change
35	amphetamine	n = 8	75 and 125 mg	oral	no significant change
^a 41	no	n = 27, pooled	50-150 mg	oral	increase after initial decrease
43	citalopram	n = 16	1.5 mg/kg	axillary	increase
46	haloperidol	n = 14	1.5 mg/kg	axillary	no significant change
44	ketanserin	n = 14	1.5 mg/kg	axillary	increase
^b 34	no	n = 74, pooled	1.35-1.8 mg/kg	axillary	increase
37	no	n = 8	0.5 and 1.5 mg/kg	finger and tympanic	no significant change
36	mCPP, amphetamine	n = 12	1 and 2 mg/kg	oral	increase
38	no	n = 9	100 mg	oral	no significant change
50	no	n = 10	2 mg/kg	^c core body and skin	increase (core), trend-increase (skin)
49	no	n = 8	1.0 and 1.6 mg/kg	tympanic	no significant change
40	tetrahydrocannabinol	n = 16	100 mg	tympanic	increase
27	reboxetine	n = 16	125 mg	tympanic	increase
48	methamphetamine	n = 11	100 mg	oral	no significant change
29	clonidine	n = 16	125 mg	tympanic	no significant change
28	duloxetine	n = 16	125 mg	tympanic	increase
30	carvedilol	n = 16	125 mg	tympanic	increase
31	doxazosin	n = 16	125 mg	tympanic	increase
^d 32	pooled analysis	n = 80, pooled	125 mg	tympanic	increase
33	methylphenidate	n = 16	125 mg	tympanic	increase
47	methylphenidate	n = 30	75 mg	tympanic	no significant change

MDMA, 3,4-methylenedioxymethamphetamine; mCPP, metachlorophenylpiperazine.

^apooled data including study 35 (n = 8) and an additional 19 subjects.

^bpooled data including studies 42, 43, 46, and 44, and data from 16 subjects from study 45.

^cingested radio-telemetry pill, chest, upper arm, thigh, and lower leg.

^dpooled data including 27-31, and 33.

temperature were observed between 90 min and 4 h after MDMA administration.

Several other smaller studies have also evaluated the thermogenic effects of MDMA. Oral temperature slightly increased after doses of 75 and 125 mg MDMA in 8 subjects, but no statistically significant differences were observed compared with placebo.³⁵ In the same study, amphetamine at an oral dose of 40 mg was also without effects on oral temperature.³⁵ A similar nonsignificant increase in oral temperature was found in another small study that included 9 subjects and a dose of 100 mg.³⁸ The same group reported significant increases in oral temperature after MDMA administration at doses of 75, 100, and 125 mg from a

pooled analysis of several studies that included doses of 50 mg (n = 2), 75 mg (n = 10), 100 mg (n = 13), 125 mg (n = 8), and 150 mg (n = 2).⁴¹ Other small studies by different research groups were also found. Harris and colleagues measured both skin (i.e., index finger) and core (i.e., tympanic) temperature after MDMA administration (0.5 and 1.5 mg/kg) in 8 subjects.³⁷ Although skin temperature decreased $5.0 \pm 4^\circ\text{C}$ from pretreatment levels after 1.5 mg/kg, it was not significantly lower than in the placebo condition in this small study.³⁷ The finding of reduced finger skin temperature is consistent with reports of cold extremities after MDMA administration and very likely reflects vasoconstriction in the periphery and reduced heat dissipation.




Figure 2. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 125 mg orally) and placebo on core body (tympenic) temperature in healthy subjects. Absolute raw data values from all subjects who participated in our 6 placebo-controlled experimental studies using a dose of MDMA of 125 mg MDMA^{27-31,33} were pooled and are presented here as mean \pm SEM of absolute tympanic temperature values in 96 healthy subjects (48 male and 48 female). MDMA significantly increased body temperature compared with placebo (repeated-measures analysis of variance: time \times drug interaction: $F_{10,940} = 19.72$, $P < 0.001$). *** for $P < 0.001$ indicate significant differences compared with placebo for individual time points based on Tukey post hoc test. MDMA or placebo was administered at $t = 0$. MDMA was administered in a quiet hospital setting and the subjects were not physically active.

Unfortunately, no other studies have measured finger temperature to confirm this finding in a larger sample. Kirkpatrick and colleagues found that MDMA at an oral dose of 100 mg had no effects on oral body temperature in 11 subjects.⁴⁸ This study also found no effects of methamphetamine (40 mg, orally) on body temperature.⁴⁸ Kolbrich and colleagues found nonsignificant elevations in tympanic temperature in 8 healthy subjects with MDMA doses of 1.0 and 1.6 mg/kg (46-150 mg).⁴⁹ Tancer and Johanson showed that MDMA at a dose of 2 mg/kg significantly increased oral body temperature in 12 subjects.³⁶ Significant increases in tympanic temperature of 0.3°C were also shown after 100 mg of MDMA in 16 subjects by Dumont and colleagues.⁴⁰ A study by Freedman, Johanson, and Tancer provided a comprehensive evaluation of the effects of 2.0 mg/kg MDMA on core and skin temperature at low (18°C) and high (30°C) ambient temperatures.⁵⁰ This also appears to be the only laboratory study of the effects of MDMA in humans in which body temperature was the primary outcome measure. In all of the other studies, body temperature was a secondary measure. Core body temperature was measured in 10 subjects using an ingested radiotelemetry pill.⁵⁰ Skin temperature was measured at the chest, upper arm, thigh, and lower leg, and a weighted average was calculated. Absolute core temperatures were higher after MDMA in the warm environment compared with the cold environment. However, core temperature was also higher in the warm environment compared with the cold environment after placebo. Thus, MDMA similarly increased core temperature at the low and high ambient temperatures compared with placebo.⁵⁰ These increases were related to increases in metabolic rate, measured by indirect calorimetry, in the same study. Skin temperature was markedly increased in the hot and decreased in the cold environment, and

MDMA produced a near-significant increase in skin temperature under both temperature conditions and compared with placebo.⁵⁰

Altogether, considering the pooled data analyses from our laboratory and those of the Freedman study, MDMA is well documented to produce an acute and dose-dependent elevation in core body temperature in healthy subjects. The increase in body temperature is also evidently rather small, in the range of 0.2-0.8°C, and does not result in hyperpyrexia ($>40^{\circ}\text{C}$) in a controlled laboratory setting. Importantly, no laboratory study observed MDMA-induced hyperpyrexia in a controlled setting. However, moderately hyperthermic body temperatures $>38.0^{\circ}\text{C}$ were documented in a substantial number of our subjects (23% after a 125 mg dose in our sample), demonstrating that MDMA induces moderate hyperthermia even in the absence of any permissive factors and at room temperature (23°C).

Neurochemistry of the thermogenic properties of MDMA in humans

Several mechanistic studies assessed the effects of pharmacological pretreatments on the response to MDMA in healthy subjects to evaluate the mediating role of different neurotransmitters and receptors. These human studies also provide important information on the mechanisms involved in MDMA-induced increases in body temperature and likely also in the more severe hyperpyrexia associated with uncontrolled use. MDMA mainly releases serotonin and norepinephrine and to a lesser extent dopamine through the corresponding presynaptic monoamine transporters.^{28,51} MDMA also interacts directly with monoamine receptors^{52,53} but only at relatively high concentrations, likely making these effects less relevant in humans. Serotonin transporter inhibitors block the interaction between MDMA with the transporter to release serotonin.²⁸ Transporter inhibitors, therefore, can be used as pharmacological tools to investigate the role of serotonin release in the mechanism of action of MDMA. Serotonin transporter inhibitors reduced the psychotropic and most physiological effects of MDMA in healthy humans,^{43,54-56} suggesting a mediating role for serotonin in most effects of MDMA in humans. Regarding the thermogenic effects of MDMA, serotonin transporter inhibition reduced MDMA-induced increases in oral⁵⁵ but not axillary body temperature.⁴³ The combined serotonin and norepinephrine transporter inhibitor duloxetine also tended to attenuate the MDMA-induced increase in body temperature in humans, but the effect was not significant.²⁸ These findings are inconclusive but are consistent with the view that both serotonin and norepinephrine are involved in the effects of MDMA on body temperature. Interestingly, in animals, serotonin transporter inhibition reduced MDMA-induced hyperthermia in mice⁵⁷ but not rats.²¹ Serotonin release is the major mediator of most of the clinical effects of MDMA, but its precise role in the thermogenic response in humans remains to be determined. The serotonin 5-HT_{2A} receptor antagonist ketanserin reduced the MDMA-induced elevation in body temperature in humans,⁴⁴ consistent with studies in rats.⁵⁸ However, in humans, ketanserin alone also reduced body temperature compared with placebo, and the effects with MDMA were therefore

mostly additive.⁴⁴ Additionally, ketanserin has α_1 -adrenergic receptor-blocking properties⁵⁹ and may reduce peripheral vascular resistance and body temperature. The serotonin 5-HT_{1A} receptor antagonist pindolol did not alter the MDMA-induced increase in body temperature in humans,⁶⁰ also consistent with preclinical data.⁵⁸ Potential dopaminergic mediation of the effects of MDMA on body temperature has not been well-studied in humans. Preclinical data suggest a role for the dopamine D₁ receptor in the mediation of hyperthermia associated with MDMA.²¹ Because no selective D₁ antagonists are available for human use, the role of the D₁ receptor has not been studied in humans. The interaction between MDMA and the dopamine D₂ receptor antagonist haloperidol was examined in healthy subjects, but MDMA did not produce significant elevations in body temperature in that study to provide meaningful results.⁴⁶ Studying the role of the dopamine transporter in MDMA-induced hyperthermia using pharmacological tools was also difficult because dopamine transporter inhibitors may not effectively block MDMA-induced dopamine release²¹ or may have effects on their own.⁶¹ In fact, the dopamine uptake inhibitor methylphenidate increased body temperature in healthy subjects when given alone but failed to alter the thermogenic response to MDMA when administered prior to MDMA.^{33,47} In contrast, MDMA did not produce an increase in body temperature in humans after pretreatment with the selective norepinephrine transporter blocker reboxetine.²⁷ Additionally, reboxetine blocked MDMA-induced increases in norepinephrine plasma levels and elevations in heart rate and blood pressure,²⁷ supporting the view that norepinephrine rather than serotonin is critical in the mediation of not only the cardiovascular but also hyperthermic response to MDMA. Further human studies examined the contributing role of different adrenergic receptors. β_1 -adrenergic receptors did not appear to be involved because the β_1 -receptor blocker pindolol did not alter the temperature response to MDMA in humans.⁶⁰ Administration of the non-selective β -receptor antagonists propranolol or nadolol also had no effect on the thermogenic response to MDMA in rats.⁶² The α_2 -adrenergic receptor agonist and sympatholytic drug clonidine, which is expected to reduce central adrenergic output, lowered body temperature in humans when given alone but not the MDMA-induced elevations in body temperature.²⁹ In contrast, the α_1 -adrenergic receptor antagonist doxazosin reduced the increase in body temperature induced by MDMA in humans.³¹ This is again consistent with the view that MDMA-induced increases in norepinephrine mediate the thermogenic effects of MDMA and that increases in body temperature are linked to cutaneous vasoconstriction that results in impaired heat dissipation, and doxazosin prevents α_1 -adrenergic receptor-mediated vasoconstriction. Peripheral vasoconstriction and improper heat dissipation have also been identified as critical mechanisms that underlie MDMA-induced core (brain) hyperthermia in rats treated with MDMA under conditions that simulate drug use in humans.²⁴ Additionally, the combined α_1 - and β_{1-3} -adrenergic receptor antagonist carvedilol effectively prevented temperature elevations in healthy subjects,^{30,63} consistent with preclinical data.⁶² This latter finding is particularly interesting because carvedilol is expected to block both MDMA-induced

heat generation by mitochondrial uncoupling^{18,64}, by blocking β_3 -adrenergic receptor- and α_1 -adrenergic receptor-mediated vasoconstriction. In fact, carvedilol more effectively reduced the hyperthermic response to MDMA compared with α_1 receptor blockade in both animals⁶² and humans.^{30,31} Similarly, both the α_1 -antagonist prazosin and the β_3 -antagonists cyanopindolol only partly attenuated body temperature increases in skeletal muscle (cyanopindolol) or core (prazosin) after MDMA and the combination of the 2 completely blocked MDMA-induced hyperthermia (muscle and core).⁶⁵ Additionally, carvedilol reduced MDMA-induced increases in both heart rate and blood pressure in healthy human subjects.³⁰ Thus, carvedilol reduced several signs of sympathetic activation by MDMA including the cardiostimulant and the thermogenic effects.

Dumont and colleagues studied the interactive effects of MDMA and tetrahydrocannabinol in healthy subjects. Tetrahydrocannabinol delayed the MDMA-induced increase in temperature, and the duration of the temperature elevation was prolonged, although the mean temperature increase was comparable to administration of MDMA alone.⁴⁰ The results indicate that tetrahydrocannabinol is unlikely to protect against MDMA-induced hyperthermia, although cannabinoids decrease body temperature in rats⁶⁶ and in contrast to previous hypotheses.⁶⁷

Several experimental human studies also tested the effects of other psychostimulants with a slightly different pharmacology than MDMA on body temperature. Various psychostimulants, including MDMA, enhance noradrenergic neurotransmission, but their relative dopaminergic vs. serotonergic activity varies. For example, Tancer and Johanson assessed the effects of MDMA, D-amphetamine (mostly a dopamine and norepinephrine releaser), and metachlorophenylpiperazine (a serotonin inhibitor and releaser) on oral temperature in the same study.³⁶ Both amphetamine and metachlorophenylpiperazine increased body temperature similarly to MDMA.³⁶ The data suggest that psychotropics with either serotonergic (metachlorophenylpiperazine) or dopaminergic (amphetamine) properties increase body temperature. Similar to amphetamine, methylphenidate (a selective dopamine and norepinephrine transporter inhibitor with no serotonergic properties) also acutely increased body temperature in humans when given at a dose of 40 mg⁴⁷ or 60 mg.³³ Cocaine enhanced the progressive increase in core body temperature during passive heating.⁶⁸ The elevation in body temperature was attributable to impaired heat dissipation, including reduced sweating and cutaneous vasodilation.⁶⁸ Similar to MDMA, cocaine has serotonergic and noradrenergic properties.⁵² Importantly, all of these recreational drugs, whether serotonergic (MDMA or metachlorophenylpiperazine) or dopaminergic (amphetamine or methylphenidate) or both (cocaine), also enhance norepinephrine transmission. Therefore, norepinephrine likely contributes to the thermogenic effects of these substances, consistent with the reducing effects of carvedilol on the temperature response to MDMA.

A series of novel psychoactive substances with structural similarity to MDMA have been implicated in hyperpyrexia. In particular, para-methoxyamphetamine and para-methoxymethamphetamine, which are occasionally sold as Ecstasy,⁶⁹ have been associated with

an especially high risk of hyperthermia.⁶⁹⁻⁷² Para-methoxyamphetamine and para-methoxymethamphetamine predominantly act on the serotonin system,⁷³ consistent with the role of serotonin in hyperthermia. Four-Methylthioamphetamine is another serotonergic compound⁷³ that has been linked to hyperthermia.⁷⁴ Other novel substances, such as 3,4-methylenedioxypropylamphetamine, which potently inhibits dopamine and norepinephrine uptake⁵² and induces marked and prolonged agitation, has also been reported to induce hyperthermia.⁷⁵ Notably, hyperthermia has also been described with the dopamine and norepinephrine transporter inhibitor methylphenidate.⁷⁶

Altogether, the mechanistic studies in humans provide support for the conclusion that MDMA mainly increases body temperature via the release of norepinephrine, which then increases metabolic heat generation and impairs heat dissipation via vasoconstriction. Additionally, the release of serotonin may also contribute to the thermogenic effects of MDMA in humans.

Management of Ecstasy-induced hyperthermia in patients

The various treatments for hyperpyrexia induced by MDMA or other psychostimulants have not been systematically evaluated in the emergency room setting. Hyperthermic complications are relatively rare, and clinical trials are unlikely to be conducted. However, as described above, several placebo-controlled mechanistic experimental studies have been conducted with healthy subjects, which can inform us on the pharmacological mechanism of MDMA-induced hyperthermia in humans and potential effects of pharmacological treatments. As a limitation, the experimental studies used doses of pure MDMA in the range of 50-150 mg while recreational users of ecstasy pills may ingest MDMA at larger doses or repeated doses. For example, in a naturalistic observational study among 49 partying people, 34 used doses of MDMA of 0-150 mg while 15 took cumulative doses of 150-280 mg.⁷⁷ An analysis of ecstasy pills from 5,786 recreational users found an average MDMA content in the ecstasy pills of 82.5 ± 35.2 mg.⁶⁹ Approximately 20% of users presenting to emergency departments with medical problems report having ingested 2 or more pills.^{5,9} Additionally, MDMA is often used in combination with other substances^{5,9} many of which may also affect body temperature.

Paramedics and emergency department personnel must recognize hyperthermia in subjects with acute substance-induced disorders. It is not uncommon that agitated subjects die of hyperpyrexia because body temperature was not measured, and elevations in body temperature went unrecognized. Agitated subjects should not be restrained. Sedation with benzodiazepines and intravenous fluid replacement are the most important acute supportive care measures in patients with substance-induced sympathomimetic toxidromes and/or agitation.^{3,5,78} The management of hyperpyrexia includes cooling (fanning, water, ice packs, ice bath, cooling blankets) and mechanical ventilation.¹⁰ Dantrolene, which acts at skeletal muscles to inhibit the release of calcium, has also been used.^{6,10,79} However, dantrolene does not inhibit the thermogenic effects of MDMA,⁸⁰ and the drug does not modulate the mechanism of MDMA-induced

hyperthermia discussed above. Nevertheless, case reports support its benefits in cases of extreme hyperpyrexia ($>42^{\circ}\text{C}$).⁶

Antipsychotics, such as haloperidol, should not be used as a routine treatment of drug-induced agitation or only with great care and after treatment with benzodiazepines. Antipsychotics are associated with hyperthermia in the context of neuroleptic malignant syndrome and some (e.g., phenothiazines) also act as anticholinergics and potentially reduce sweating and thus heat dissipation by evaporation. Additionally, haloperidol has been shown to enhance acute anxiety and the negative mood effects of MDMA⁴⁶ and psilocybin.⁸¹ Thus, the use of this antipsychotic medication may actually enhance adverse drug effects, at least in certain situations. The atypical antipsychotic clozapine has been shown to reverse hyperthermia and cutaneous vasoconstriction induced by MDMA in rats or rabbits⁸² but human data to support its clinical use are lacking. Hyperthermia is often associated with other signs of sympathomimetic stimulation, including agitation, tachycardia, and hypertension. Benzodiazepines are also beneficial in the treatment of these symptoms. However, additional hypertensive treatment with vasodilators, such as nitrates, may be needed. Adrenergic receptor antagonists can be useful. However, β blockade without α blockade should be avoided in drug-induced sympathomimetic toxicity because of the unopposed α -adrenergic receptor stimulation that enhances vasoconstriction⁸³ and results in further increases in blood pressure^{60,84} and possibly body temperature. In contrast, α blockade reduced the blood pressure response to MDMA and elevations in body temperature,³¹ and combined α/β blockade reduced MDMA-induced increases in blood pressure, heart rate, and body temperature^{30,63} and blood pressure response to cocaine.⁸⁵⁻⁸⁷ Accordingly, α blockers (e.g., phentolamine) or α/β blockers (e.g., carvedilol) could be useful in situations of extreme sympathomimetic stimulation, although real-world clinical data are mostly lacking. Phentolamine was successfully used to treat a hypertensive emergency caused by amphetamine overdose.⁸⁸

Besides from hyperthermia, brain edema is another severe complication of MDMA use. MDMA induces a syndrome of inappropriate secretion of antidiuretic hormone⁸⁹⁻⁹¹ which may lead to symptomatic hyponatremia including brain edema in particular in women.⁹²⁻⁹⁴ Thus, excessive water consumption but also fluid treatment can be potentially dangerous in the prevention or the treatment of MDMA-induced hyperthermia. Additionally, animal studies indicate that the blood-brain barrier is disrupted during MDMA-induced hyperthermia also leading to brain edema.⁹⁵

Conclusion

MDMA increases body temperature in humans. However, hyperpyrexia ($>40^{\circ}\text{C}$) is not seen in controlled laboratory settings. The MDMA-induced elevations in body temperature in humans appear to depend on the MDMA-induced release of norepinephrine and involve cutaneous vasoconstriction and likely also enhanced metabolic heat generation. The role of serotonin needs further clarification. The management of overdose cases

includes sedation treatment with benzodiazepines, intravenous fluid replacement, and additional cooling and mechanical ventilation in severe cases.

Acknowledgments

The author thanks Yasmin Schmid for data preparation and comments on the manuscript.

Funding

This work was supported by the Swiss National Science Foundation (no. 320030_149493/1).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

- Green AR, Mehan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxyamphetamine (MDMA, "ecstasy"). *Pharmacol Rev* 2003; 55:463-508; PMID:12869661; <http://dx.doi.org/10.1124/pr.55.3.3>.
- Parrott AC. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. *Drug Alcohol Depend* 2012; 121:1-9; PMID:21924843; <http://dx.doi.org/10.1016/j.drugalcdep.2011.08.012>.
- Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K. Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. *Hum Exp Toxicol* 2011; 30:259-66; PMID:20488845; <http://dx.doi.org/10.1177/0960327110370984>.
- Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxyamphetamine ("ecstasy"). *Lancet* 1992; 340:384-7; PMID:1353554; [http://dx.doi.org/10.1016/0140-6736\(92\)91469-O](http://dx.doi.org/10.1016/0140-6736(92)91469-O).
- Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to Ecstasy use: case-series of emergency department visits. *Swiss Med Wkly* 2005; 135:652-7; PMID:16380853.
- Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. *CJEM* 2010; 12:435-42; PMID:20880437.
- Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxyamphetamine (MDMA, ecstasy) and its derivatives. *Br J Pharmacol* 2010; 160:1029-44; PMID:20590597.
- Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. *Health Technol Assess* 2009; 13:iii-iv, ix-xii, 1-315; PMID:19195429.
- Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A. "Saturday night fever:" ecstasy related problems in a London accident and emergency department. *J Accid Emerg Med* 1998; 15:322-6; PMID:9785160; <http://dx.doi.org/10.1136/emj.15.5.322>.
- Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. *Br J Anaesth* 2006; 96:678-85; PMID:16595612; <http://dx.doi.org/10.1093/bja/ael078>.
- Rusyniak DE, Tandy SL, Hekmatyar SK, Mills E, Smith DJ, Bansal N, MacLellan D, Harper ME, Sprague JE. The role of mitochondrial uncoupling in 3,4-methylenedioxyamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis. *J Pharmacol Exp Ther* 2005; 313:629-39; PMID:15644431; <http://dx.doi.org/10.1124/jpet.104.079236>.
- McAllen KJ, Schwartz DR. Adverse drug reactions resulting in hyperthermia in the intensive care unit. *Crit Care Med* 2010; 38:S244-52; PMID:20502177.
- Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. *Med Clin North Am* 2005; 89:1277-96; PMID:16227063; <http://dx.doi.org/10.1016/j.mcna.2005.06.002>.
- Green AR, O'Shea E, Colado MI. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. *Eur J Pharmacol* 2004; 500:3-13; PMID:15464016; <http://dx.doi.org/10.1016/j.ejphar.2004.07.006>.
- Kiyatkin EA. The hidden side of drug action: brain temperature changes induced by neuroactive drugs. *Psychopharmacology (Berl)* 2013; 225:765-80; PMID:23274506; <http://dx.doi.org/10.1007/s00213-012-2957-9>.
- Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005; 352:1112-20; PMID:15784664; <http://dx.doi.org/10.1056/NEJMra041867>.
- Silins E, Copeland J, Dillon P. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. *Aust N Z J Psychiatry* 2007; 41:649-55; PMID:17620161; <http://dx.doi.org/10.1080/00048670701449237>.
- Mills EM, Banks ML, Sprague JE, Finkel T. Pharmacology: uncoupling the agony from ecstasy. *Nature* 2003; 426:403-4; PMID:14647371; <http://dx.doi.org/10.1038/426403a>.
- Mills EM, Rusyniak DE, Sprague JE. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxyamphetamine. *J Mol Med* 2004; 82:787-99; PMID:15602689; <http://dx.doi.org/10.1007/s00109-004-0591-7>.
- Saadat KS, O'Shea E, Colado MI, Elliott JM, Green AR. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature. *Psychopharmacology (Berl)* 2005; 179:884-90; PMID:15650843; <http://dx.doi.org/10.1007/s00213-004-2106-1>.
- Mehan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxyamphetamine (MDMA, 'ecstasy') to rats. *Br J Pharmacol* 2002; 135:170-80; PMID:11786492.
- Schutte JK, Schafer U, Becker S, Oldewurtel C, Starosse A, Singler P, Richard A, Wappler F, Gerbershagen MU. Three,4-Methylenedioxyamphetamine induces a hyperthermic and hypermetabolic crisis in pigs with and without a genetic disposition for malignant hyperthermia. *Eur J Anaesthesiol* 2013; 30:29-37; PMID:23138574; <http://dx.doi.org/10.1097/EJA.0b013e32835a1127>.
- Dafters RI. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. *Physiol Behav* 1995; 58:877-82; PMID:8577883; [http://dx.doi.org/10.1016/0031-9384\(95\)00136-7](http://dx.doi.org/10.1016/0031-9384(95)00136-7).
- Kiyatkin EA, Kim AH, Wakabayashi KT, Baumann MH, Shaham Y. Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. *J Neurosci* 2014; 34:7754-62; PMID:24899699; <http://dx.doi.org/10.1523/JNEUROSCI.0506-14.2014>.
- Brown PL, Kiyatkin EA. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. *Eur J Neurosci* 2004; 20:51-8; PMID:15245478; <http://dx.doi.org/10.1111/j.0953-816X.2004.03453.x>.
- Patel MM, Belson MG, Longwater AB, Olson KR, Miller MA. Methylenedioxyamphetamine (ecstasy)-related hyperthermia. *J Emerg Med* 2005; 29:451-4; PMID:16243206; <http://dx.doi.org/10.1016/j.jemermed.2005.05.007>.
- Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. *Clin Pharmacol Ther* 2011; 90:246-55; PMID:21677639; <http://dx.doi.org/10.1038/clpt.2011.78>.
- Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Hoener MC, Liechti ME. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. *PLoS One* 2012; 7:e36476; PMID:22574166; <http://dx.doi.org/10.1371/journal.pone.0036476>.
- Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME. Effects of the α_2 -adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxyamphetamine in healthy volunteers. *J Pharmacol Exp Ther* 2012; 340:286-94; PMID:22034656; <http://dx.doi.org/10.1124/jpet.111.188425>.
- Hysek CM, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, Liechti ME. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. *Br J Pharmacol* 2012; 166:2277-88; PMID:22404145.
- Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME. α -Adrenergic receptors contribute to the acute effects of MDMA in humans. *J Clin Psychopharmacol* 2013; 33:658-666; PMID:23857311; <http://dx.doi.org/10.1097/JCP.0b013e3182979d32>.
- Hysek CM, Liechti ME. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. *Psychopharmacology (Berl)* 2012; 224:363-76; PMID:22700038; <http://dx.doi.org/10.1007/s00213-012-2761-6>.
- Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, Liechti ME. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. *Int J Neuropsychopharmacol* 2014; 17:371-81; PMID:24103254; <http://dx.doi.org/10.1017/S1461145713001132>.
- Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. *Psychopharmacology (Berl)* 2001; 154:161-8; PMID:111314678; <http://dx.doi.org/10.1007/s002130000648>.
- Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxyamphetamine in humans. *J Pharmacol Exp Ther* 1999; 290:136-45; PMID:10381769.
- Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. *Drug Alcohol Depend* 2003; 72:33-44; PMID:14563541; [http://dx.doi.org/10.1016/S0376-8716\(03\)00172-8](http://dx.doi.org/10.1016/S0376-8716(03)00172-8).

37. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxyamphetamine (MDMA) in humans. *Psychopharmacol (Berl)* 2002; 162:396-405; PMID:12172693; <http://dx.doi.org/10.1007/s00213-002-1131-1>.
38. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. *Psychopharmacol (Berl)* 2004; 173:364-75; PMID:15071716; <http://dx.doi.org/10.1007/s00213-004-1789-7>.
39. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxyamphetamine in humans: methodological considerations and preliminary observations. *Behav Brain Res* 1996; 73:103-7; PMID:8788485; [http://dx.doi.org/10.1016/0166-4328\(96\)00078-2](http://dx.doi.org/10.1016/0166-4328(96)00078-2).
40. Dumont GJ, Kramers C, Sweep FC, Touw DJ, van Hasselt JG, de Kam M, van Gerven JM, Buitelaar JK, Verkes RJ. Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. *Clin Pharmacol Ther* 2009; 86:160-6; PMID:19440186; <http://dx.doi.org/10.1038/clpt.2009.62>.
41. de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J. Pharmacology of MDMA in humans. *Ann N Y Acad Sci* 2000; 914:225-37; PMID:11085324; <http://dx.doi.org/10.1111/j.1749-6632.2000.tb05199.x>.
42. Vollenweider FX, Gamma A, Liechti ME, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. *Neuropsychopharmacology* 1998; 19:241-51; PMID:9718588; [http://dx.doi.org/10.1016/S0893-133X\(98\)00013-X](http://dx.doi.org/10.1016/S0893-133X(98)00013-X).
43. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxyamphetamine ("Ecstasy") in healthy volunteers. *J Psychopharmacol* 2000; 14:269-74; PMID:11106307; <http://dx.doi.org/10.1177/026988110001400313>.
44. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT₂ antagonist ketanserin in healthy humans. *Neuropsychopharmacology* 2000; 23:396-404; PMID:10989266; [http://dx.doi.org/10.1016/S0893-133X\(00\)00126-3](http://dx.doi.org/10.1016/S0893-133X(00)00126-3).
45. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. Three,4-Methylenedioxyamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [¹⁵O]-PET in healthy humans. *Neuropsychopharmacology* 2000; 23:388-95; PMID:10989265; [http://dx.doi.org/10.1016/S0893-133X\(00\)00130-5](http://dx.doi.org/10.1016/S0893-133X(00)00130-5).
46. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. *Eur Neuropsychopharmacol* 2000; 10:289-295; PMID:10871712; [http://dx.doi.org/10.1016/S0924-977X\(00\)00086-9](http://dx.doi.org/10.1016/S0924-977X(00)00086-9).
47. Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. *J Psychopharmacol* 2014; 28:847-56; PMID:25052243; <http://dx.doi.org/10.1177/0269881114542454>.
48. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxyamphetamine (MDMA) in humans. *Psychopharmacol (Berl)* 2012; 219:109-22; PMID:21713605; <http://dx.doi.org/10.1007/s00213-011-2383-4>.
49. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Physiological and subjective responses to controlled oral 3,4-methylenedioxyamphetamine administration. *J Clin Psychopharmacol* 2008; 28:432-40; PMID:18626271; <http://dx.doi.org/10.1097/JCP.0b013e31817cf470>.
50. Freedman RR, Johanson CE, Tancer ME. Thermoregulatory effects of 3,4-methylenedioxyamphetamine (MDMA) in humans. *Psychopharmacol (Berl)* 2005; 183:248-56; PMID:16163516; <http://dx.doi.org/10.1007/s00213-005-0149-6>.
51. Verrico CD, Miller GM, Madras BK. MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. *Psychopharmacology* 2007; 189:489-503; PMID:16220332; <http://dx.doi.org/10.1007/s00213-005-0174-5>.
52. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener M, Liechti ME. Pharmacological characterization of designer cathinones in vitro. *Br J Pharmacol* 2013; 168:458-70; PMID:22897747.
53. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxyamphetamine) at various brain recognition sites. *Eur J Pharmacol* 1988; 149:159-63; PMID:2899513; [http://dx.doi.org/10.1016/0014-2999\(88\)90056-8](http://dx.doi.org/10.1016/0014-2999(88)90056-8).
54. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxyamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. *Neuropsychopharmacology* 2000; 22:513-21; PMID:10731626; [http://dx.doi.org/10.1016/S0893-133X\(99\)00148-7](http://dx.doi.org/10.1016/S0893-133X(99)00148-7).
55. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B, Segura M, de la Torre R. Pharmacological interaction between 3,4-methylenedioxyamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. *J Pharmacol Exp Ther* 2007; 323:954-62; PMID:17890444; <http://dx.doi.org/10.1124/jpet.107.129056>.
56. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxyamphetamine (MDMA) in humans. *Psychopharmacology* 2007; 189:565-73; PMID:17047932; <http://dx.doi.org/10.1007/s00213-006-0576-z>.
57. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ("ecstasy") on the 5-HT and dopamine concentrations in mouse brain. *Neuropharmacology* 2001; 40:65-74; PMID:11077072; [http://dx.doi.org/10.1016/S0028-3908\(00\)00106-4](http://dx.doi.org/10.1016/S0028-3908(00)00106-4).
58. Nash JF Jr, Meltzer HY, Gudelsky GA. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxyamphetamine. *J Pharmacol Exp Ther* 1988; 245:873-9; PMID:2898523.
59. Brogden RN, Sorkin EM. Ketanserin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. *Drugs* 1990; 40:903-49; PMID:2079001; <http://dx.doi.org/10.2165/00003495-199040060-00010>.
60. Hysek CM, Vollenweider FX, Liechti ME. Effects of a β -blocker on the cardiovascular response to MDMA (ecstasy). *Emerg Med J* 2010; 27:586-9; PMID:20378736; <http://dx.doi.org/10.1136/emj.2009.079905>.
61. Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypropylvalerone antagonist methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. *BMC Res Notes* 2013; 6:220; PMID:23734766; <http://dx.doi.org/10.1186/1756-0500-6-220>.
62. Sprague JE, Moze P, Caden D, Rusyniak DE, Holmes C, Goldstein DS, Mills EM. Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxyamphetamine (MDMA, Ecstasy) in an animal model. *Crit Care Med* 2005; 33:1311-16; PMID:15942349.
63. Hysek CM, Schmid Y, Rickli A, Liechti ME. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: lost in translation. *Br J Pharmacol* 2013; 170:1273-75; PMID:24033079.
64. Sprague JE, Brucher RE, Mills EM, Caden D, Rusyniak DE. Attenuation of 3,4-methylenedioxyamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α_1 - plus β_3 -adrenoceptor antagonists. *Br J Pharmacol* 2004; 142:667-70; PMID:15159279.
65. Sprague JE, Banks ML, Cook VJ, Mills EM. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxyamphetamine (Ecstasy). *J Pharmacol Exp Ther* 2003; 305:159-66; PMID:12649364; <http://dx.doi.org/10.1124/jpet.102.044982>.
66. Rawls SM, Cowan A, Tallarida RJ, Geller EB, Adler MW. N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4-(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia. *J Pharmacol Exp Ther* 2002; 303:395-402; PMID:12235276; <http://dx.doi.org/10.1124/jpet.102.037473>.
67. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxyamphetamine): an analysis of their neuropsychobiological interactions in recreational users. *J Neural Transm* 2007; 114:959-68; PMID:17520319; <http://dx.doi.org/10.1007/s00702-007-0715-7>.
68. Crandall CG. Vongpatanasin W, Victor RG. Mechanism of cocaine-induced hyperthermia in humans. *Ann Intern Med* 2002; 136:785-91; PMID:12044126.
69. Brunt TM, Koeter MW, Niesink RJ, van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. *Psychopharmacology (Berl)* 2012; 220:751-62; PMID:21993879; <http://dx.doi.org/10.1007/s00213-011-2529-4>.
70. Lurie Y, Gopher A, Lavon O, Almog S, Sulimani L, Bentur Y. Severe paramethoxyamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel. *Clin Toxicol (Phila)* 2012; 50:39-43; PMID:22148985; <http://dx.doi.org/10.3109/15563650.2011.635148>.
71. Refstad S. Paramethoxyamphetamine (PMA) poisoning: a 'party drug' with lethal effects. *Acta Anaesthesiol Scand* 2003; 47:1298-9; PMID:14616331; <http://dx.doi.org/10.1046/j.1399-6576.2003.00245.x>.
72. Johansen SS, Hansen AC, Muller IB, Lundemose JB, Franzmann MB. Three fatal cases of PMA and PMMA poisoning in Denmark. *J Anal Toxicol* 2003; 27:253-6; PMID:12820749; <http://dx.doi.org/10.1093/jat/27.4.253>.
73. Simmler LD, Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. *Neuropharmacology* 2014; 79:152-60; PMID:24275046; <http://dx.doi.org/10.1016/j.neuropharm.2013.11.008>.
74. De Letter EA, Coopman VA, Cordonnier JA, Piette MH. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinicopathological findings. *Int J Legal Med* 2001; 114:352-6; PMID:11508803; <http://dx.doi.org/10.1007/s004140100204>.

75. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypropylvalerone. *Ann Emerg Med* 2012; 60:103-5; PMID:22387085; <http://dx.doi.org/10.1016/j.annemergmed.2012.01.005>.
76. Peyre H, Delorme R. A case of severe hyperthermia after administration of methylphenidate. *J Clin Psychopharmacol* 2012; 32:299-300; PMID:22388166; <http://dx.doi.org/10.1097/JCP.0b013e3182499677>.
77. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. Pill content, dose and resulting plasma concentrations of 3,4-methylenedioxyamphetamine (MDMA) in recreational 'ecstasy' users. *Addiction* 2011; 106:1293-300; PMID:21320226; <http://dx.doi.org/10.1111/j.1360-0443.2011.03399.x>.
78. Dubin WR, Feld JA. Rapid tranquilization of the violent patient. *Am J Emerg Med* 1989; 7:313-20; PMID:2565724; [http://dx.doi.org/10.1016/0735-6757\(89\)90179-4](http://dx.doi.org/10.1016/0735-6757(89)90179-4).
79. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxyamphetamine (MDMA or "Ecstasy"). *Psychopharmacology* 1995; 119:247-60; PMID:7675958; <http://dx.doi.org/10.1007/BF02246288>.
80. Rusyniak DE, Banks ML, Mills EM, Sprague JE. Dantrolene use in 3,4-methylenedioxyamphetamine (ecstasy)-mediated hyperthermia. *Anesthesiology* 2004; 101:263; author reply 264; PMID:15220814; <http://dx.doi.org/10.1097/00000542-200407000-00053>.
81. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* 1998; 9:3897-902; PMID:9875725; <http://dx.doi.org/10.1097/00001756-199812010-00024>.
82. Blessing WW, Seaman B, Pedersen NP, Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxyamphetamine (ecstasy) in rabbits and rats. *J Neurosci* 2003; 23:6385-91; PMID:12867524.
83. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD. Potentiation of cocaine-induced coronary vasoconstriction by β -adrenergic blockade. *Ann Intern Med* 1990; 112:897-903; PMID:1971166.
84. Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of cocaine intoxication. *Ann Emerg Med* 1985; 14:1112-3; PMID:4051280; [http://dx.doi.org/10.1016/S0196-0644\(85\)80934-3](http://dx.doi.org/10.1016/S0196-0644(85)80934-3).
85. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. *Am J Med* 1993; 94:608-10; PMID:8506886; [http://dx.doi.org/10.1016/0002-9343\(93\)90212-8](http://dx.doi.org/10.1016/0002-9343(93)90212-8).
86. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. *Pharmacol Biochem Behav* 2000; 65:255-9; PMID:10672977; [http://dx.doi.org/10.1016/S0091-3057\(99\)00201-4](http://dx.doi.org/10.1016/S0091-3057(99)00201-4).
87. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. *Drug Alcohol Depend* 2000; 60:69-76; PMID:10821991; [http://dx.doi.org/10.1016/S0376-8716\(99\)00143-X](http://dx.doi.org/10.1016/S0376-8716(99)00143-X).
88. Spaziani ML, Schult RF, Wiegand TJ. Lisdexamphetamine ingestion resulting in hypertensive emergency treated with phentolamine. *Clin Toxicol (Phila)* 2014; 52:406; <http://dx.doi.org/10.3109/15563650.2014.906213>.
89. Holden R Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). *Lancet* 1996; 347:1052; PMID:8606600; [http://dx.doi.org/10.1016/S0140-6736\(96\)90196-8](http://dx.doi.org/10.1016/S0140-6736(96)90196-8).
90. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxyamphetamine (MDMA, 'ecstasy') ingestion. *QJM* 2002; 95:431-437; PMID:12096147; <http://dx.doi.org/10.1093/qjmed/95.7.431>.
91. Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. *J Clin Endocrinol Metab* 2011; 96:2844-50; PMID:21715530; <http://dx.doi.org/10.1210/jc.2011-1143>.
92. Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR. Patterns of ecstasy-associated hyponatremia in California. *Ann Emerg Med* 2007; 49:164-71; PMID:17084942; <http://dx.doi.org/10.1016/j.annemergmed.2006.09.018>.
93. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. Hyponatremia associated with 3,4-methylenedioxy-methylamphetamine ("Ecstasy") abuse. *Am J Med Sci* 2003; 326:89-93; PMID:12920440; <http://dx.doi.org/10.1097/00000441-200308000-00006>.
94. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. *Dtsch Med Wochenschr* 2001; 126:809-11; PMID:11499262; <http://dx.doi.org/10.1055/s-2001-15702>.
95. Sharma HS, Ali SF. Acute administration of 3,4-methylenedioxyamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. *Ann N Y Acad Sci* 2008; 1139:242-58; PMID:18991870; <http://dx.doi.org/10.1196/annals.1432.052>.